Search Patents
  • NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS
    Publication number: 20220401550
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: August 11, 2022
    Publication date: December 22, 2022
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
    Publication number: 20240042014
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 8, 2024
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • Coronavirus vaccine
    Patent number: 10973909
    Abstract: The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in an individual. The polypeptides and vaccines comprise T cell and/or B cell epitopes that are immunogenic in a high percentage of individuals in the human population.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: April 13, 2021
    Assignee: PepTC Vaccines Limited
    Inventors: Zsolt Csiszovszki, Orsolya Lörincz, Levente Molnár, Péter Páles, Katalin Pántya, Eszter Somogyi, József Tóth, Enikö R. Töke
  • NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
    Publication number: 20240000922
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 4, 2024
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11969467
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: April 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11911462
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: February 27, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11759516
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: September 19, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Nucleic acid vaccine against the SARS-CoV-2 coronavirus
    Patent number: 11964013
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: April 23, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • SARS-CoV-2 Subunit Vaccine and Microneedle Array Delivery System
    Publication number: 20220087930
    Abstract: A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 24, 2022
    Inventors: Andrea Gambotto, Louis Falo, JR., Eun Kim
  • Composition and Method of mRNA Vaccines Against Novel Coronavirus Infection
    Publication number: 20220040292
    Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.
    Type: Application
    Filed: February 8, 2021
    Publication date: February 10, 2022
    Inventors: Shenggao TANG, Dong SHEN, Chun LU, Ziyang HE, Jiaxi HE, Patrick Y. LU
  • COMPOSITION AND METHOD OF mRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION
    Publication number: 20230108926
    Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 6, 2023
    Applicant: RNAimmune, Inc.
    Inventors: Shenggao TANG, Dong SHEN, Chun LU, Ziyang HE, Jiaxi HE, Patrick Y. LU
  • CORONAVIRUS VACCINE COMPOSITIONS AND METHODS OF USE
    Publication number: 20230190919
    Abstract: Provided is a method of enhancing an antigen-induced long-lasting immune response in a host comprising administering to a host an effective amount of: (a) a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen; and (b) a Coronavirus antigen that is not expressed by the rabies virus. Also provided are related compositions, kits and vaccines.
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Inventors: Douglas Craig Hooper, Bernhardt Dietzschold
  • SARS-CoV-2 subunit vaccine and microneedle array delivery system
    Patent number: 11737974
    Abstract: A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: August 29, 2023
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Andrea Gambotto, Louis Falo, Jr., Eun Kim
  • SARS-CoV-2 subunit vaccine and microneedle array delivery system
    Patent number: 11213482
    Abstract: A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: January 4, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Educat
    Inventors: Andrea Gambotto, Louis Falo, Jr., Eun Kim
  • A LIVE ATTENUATED MEASLES VIRUS VECTORED VACCINE FOR SARS-COV-2
    Publication number: 20230310581
    Abstract: Disclosed herein is a live attenuated recombinant measles virus (rMeV)-based coronavirus vaccine containing a SARS-CoV-2 spike (S) protein that has at least one mutation to remove a glycosylation site. In some embodiments, the rMeVs-based coronavirus vaccine contains full-length stabilized pre-fusion and native S proteins, S proteins of SARS-CoV-2 variants, truncated S proteins lacking its transmembrane and cytoplasmic domains, S proteins lacking glycosylation sites, the monomeric and trimeric receptor-binding domain (RBD), the monomeric and trimeric S1 protein, Fc-fused RBD, or Fc-fused S1 protein. Also disclosed is a live attenuated recombinant coronavirus vaccine, wherein a stabilized prefusion spike (S) protein is inserted into a viral vector genome.
    Type: Application
    Filed: April 27, 2021
    Publication date: October 5, 2023
    Inventors: Jianrong LI, Stefan NIEWIESK, Anzhong LI, Mijia LU
  • Methods, Compositions, and Systems for Detecting Coronavirus Neutralizing Antibodies
    Publication number: 20220065869
    Abstract: The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.
    Type: Application
    Filed: June 25, 2021
    Publication date: March 3, 2022
    Inventors: Christos J. Petropoulos, Mary T. Wrin, Danielle DiTirro
  • CORONAVIRUS VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO
    Publication number: 20230143228
    Abstract: This disclosure relates to methods of promoting immune responses against coronavirus, such as SARS-CoV-2, and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for coronavirus comprising administering to the subject a composition disclosed herein. In certain embodiments, the composition comprises a recombinant virus such as recombinant MVA that encodes a coronavirus spike protein. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 986. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 987.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 11, 2023
    Inventors: Rama Rao AMARA, Sailaja GANGADHARA, Nanda Kishore ROUTHU
  • CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME
    Publication number: 20230355745
    Abstract: Disclosed are a novel coronavirus-derived receptor-binding domain variant having reduced ACE2-binding affinity, a fusion protein comprising the same, and the use thereof. It is possible to overcome the drawbacks of conventional vaccines using the coronavirus spike protein or receptor-binding domain thereof, wherein the reduced ACE2 expression due to binding to ACE2 and negative feedback may lead to side effects of the lungs or heart, and in particular, may be fatal to patients suffering from underlying diseases of the lungs or heart. In particular, the fusion protein constructed by fusing the coronavirus receptor-binding domain with the Fc domain is imparted with a greatly improved in-vivo half-life, and has superior efficacy by further combining N protein, M protein, ORF protein, or the like of SARS-CoV-2 therewith through additional modification and thus is highly applicable to a multivalent immunogenic composition.
    Type: Application
    Filed: January 29, 2021
    Publication date: November 9, 2023
    Inventors: Myoung Ho JANG, Jae Chan PARK, Young Joo CHOI, Young Hyun PARK, Gil-Jung KIM, Seung Mi JEONG, Yeon Soo PARK, Su Bin LEE
  • CORONAVIRUS VACCINE
    Publication number: 20240000921
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
    Type: Application
    Filed: June 26, 2023
    Publication date: January 4, 2024
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
  • COMPOSITIONS AND DEVICES FOR VACCINE RELEASE AND USES THEREOF
    Publication number: 20230270842
    Abstract: Microneedle and microneedle devices including implantable tips (e.g., silk-based tips) for sustained dermal delivery of a coronavirus and/or influenza vaccine, kits, as well as methods of manufacturing and using the same are described herein. In other embodiments, compositions and methods for controlled- or sustained-administration of a coronavirus vaccine and/or an influenza vaccine to provide improved immunogenicity and/or broad-spectrum immunity to a subject are also described.
    Type: Application
    Filed: November 21, 2022
    Publication date: August 31, 2023
    Applicant: VAXESS TECHNOLOGIES, INC.
    Inventors: Michael A. Schrader, Kathryn M. Kosuda, Jonathan A. Kluge, Kimberly M. Cirelli, Emily L. Borkowski, Cassie L. Caudill, Matthew Dirckx, Nickolas W. Hartman, Livio Valenti
Narrow Results

Filter by US Classification